BR112013024923A2 - novo anticorpo receptor de il-23 anti-humano - Google Patents

novo anticorpo receptor de il-23 anti-humano

Info

Publication number
BR112013024923A2
BR112013024923A2 BR112013024923A BR112013024923A BR112013024923A2 BR 112013024923 A2 BR112013024923 A2 BR 112013024923A2 BR 112013024923 A BR112013024923 A BR 112013024923A BR 112013024923 A BR112013024923 A BR 112013024923A BR 112013024923 A2 BR112013024923 A2 BR 112013024923A2
Authority
BR
Brazil
Prior art keywords
human
antibody
receptor antibody
new anti
amino acid
Prior art date
Application number
BR112013024923A
Other languages
English (en)
Inventor
Hiromu Sato
Katsunari Taguchi
Makoto Ohori
Takanori Sasaki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112013024923A2 publication Critical patent/BR112013024923A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

novo anticorpo receptor de il-23 anti-humano problema. um objetivo da presente invenção é proporcionar um anticorpo il-23r anti-humano dotado de excelente atividade e/ou reatividade cruzada comparada aos anticorpos il-23r convencionais, e meios para usar o anticorpo para evitar ou tratar as diversas doenças nas quais a il-23r humana está envolvida em patogênese. meios para solução. um anticorpo il-23r anti-humano compreendendo uma região variável de cadeia pesada que consiste da sequência de amino ácido mostrada por seq id no: 5, 9, 13, 17, 21, 25 ou 29 e uma região variável de cadeia leve que consiste da sequência de amino ácido mostrada por seq id no: 7, 11, 15, 19, 23, 27 ou 31.
BR112013024923A 2011-04-01 2012-03-30 novo anticorpo receptor de il-23 anti-humano BR112013024923A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011081982 2011-04-01
PCT/JP2012/058531 WO2012137676A1 (ja) 2011-04-01 2012-03-30 新規抗ヒトｉｌ－２３受容体抗体

Publications (1)

Publication Number Publication Date
BR112013024923A2 true BR112013024923A2 (pt) 2016-11-22

Family

ID=46969077

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024923A BR112013024923A2 (pt) 2011-04-01 2012-03-30 novo anticorpo receptor de il-23 anti-humano

Country Status (16)

Country Link
US (1) US9556276B2 (pt)
EP (1) EP2695897B1 (pt)
JP (1) JP5971238B2 (pt)
KR (1) KR20140032392A (pt)
CN (2) CN104817641B (pt)
AR (1) AR085824A1 (pt)
BR (1) BR112013024923A2 (pt)
CA (1) CA2831751A1 (pt)
EA (1) EA026119B1 (pt)
ES (1) ES2728438T3 (pt)
MX (1) MX347955B (pt)
PL (1) PL2695897T3 (pt)
PT (1) PT2695897T (pt)
TR (1) TR201908197T4 (pt)
TW (1) TW201249867A (pt)
WO (1) WO2012137676A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2701064T3 (es) * 2012-02-28 2019-02-20 Astellas Pharma Inc Novedoso anticuerpo antirreceptor IL-23 humano
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
AU2017230091B2 (en) * 2016-03-10 2022-04-07 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
CN113698484B (zh) * 2021-10-13 2023-07-18 浙江博锐生物制药有限公司 抗il-23r抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2213148T3 (es) 1993-03-11 2004-08-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticuerpo monoclonal dirigido contra el vih.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR20100014568A (ko) * 2007-02-28 2010-02-10 쉐링 코포레이션 가공된 항-ｉｌ-23ｒ 항체
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment

Also Published As

Publication number Publication date
MX2013011414A (es) 2014-04-14
ES2728438T3 (es) 2019-10-24
TR201908197T4 (tr) 2019-06-21
AR085824A1 (es) 2013-10-30
CN104817641A (zh) 2015-08-05
CN104817641B (zh) 2018-06-26
EP2695897A9 (en) 2015-10-07
EA026119B1 (ru) 2017-03-31
CN103459426B (zh) 2015-05-13
WO2012137676A1 (ja) 2012-10-11
MX347955B (es) 2017-05-16
EP2695897A1 (en) 2014-02-12
EP2695897B1 (en) 2019-05-01
PT2695897T (pt) 2019-06-12
CA2831751A1 (en) 2012-10-11
TW201249867A (en) 2012-12-16
EA201391453A1 (ru) 2014-01-30
PL2695897T3 (pl) 2019-08-30
US9556276B2 (en) 2017-01-31
JPWO2012137676A1 (ja) 2014-07-28
EP2695897A4 (en) 2015-03-18
US20140275490A1 (en) 2014-09-18
JP5971238B2 (ja) 2016-08-17
KR20140032392A (ko) 2014-03-14
CN103459426A (zh) 2013-12-18

Similar Documents

Publication Publication Date Title
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
ES2667568T3 (es) Anticuerpo anti-B7-H3
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
BR112012021327A2 (pt) anticorpo monoclonal anti-her2 completamente humano, método de preparação e uso do mesmo.
NZ706377A (en) Il-6 antagonists and uses thereof
CL2019002658A1 (es) Composiciones optimizadas de anticuerpos para el tratamiento de desórdenes oculares.
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
CR20150121A (es) Moléculas de enlace a il-18
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
BR112014008775A2 (pt) camundongo de cadeia pesada de imunoglobulina restrita
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
UA110358C2 (en) Molecules of antibody binding il-17a and il-17f
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
BR112016002743A2 (pt) novo anticorpo de receptor de tslp anti-humana
EA201490433A1 (ru) Новое антитело против ngf человека
BR112013024923A2 (pt) novo anticorpo receptor de il-23 anti-humano
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112017000689A2 (pt) novo anticorpo tie-2 anti-humano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 28/01/2020.